Pharma Two B Ltd.

Overview

Overview

Pharma Two B Ltd. is an Israeli biotechnology company dedicated to developing novel treatments for Parkinson's disease (PD) and other central nervous system disorders through innovative fixed-dose combination therapies. Founded in 2007 and headquartered in Netanya, Israel, the company has established itself as a pioneer in developing enhanced therapeutic regimens that combine proven agents in novel formulations to improve patient outcomes and simplify treatment administration.

The company's name reflects its focus on combination therapies—two biological agents working synergistically to provide enhanced therapeutic benefit. Pharma Two B's strategic approach leverages the well-established efficacy of existing Parkinson's disease medications while addressing their limitations through optimized fixed-dose combinations that reduce pill burden, improve compliance, and potentially enhance clinical outcomes["@jankovic2015; @schapira2019"].

Company Profile

| Attribute | Value |
|-----------|-------|
| Headquarters | Netanya, Israel |
| Founded | 2007 |
| Ticker | PHRM (NASDAQ) |
| Focus | CNS disorders, Parkinson's disease |
| Employees | ~50 (as of 2024) |

Pharma Two B operates from modern research facilities in the Israeli "Pharmaceutical Valley" corridor, benefiting from proximity to leading academic medical centers including Tel Aviv University and the Rabin Medical Center, both of which have been instrumental in the company's clinical development programs.

Therapeutic Approach

Fixed-Dose Combination Strategy

Pharma Two B's core therapeutic strategy focuses on fixed-dose combination (FDC) therapies for Parkinson's disease. This approach addresses several critical challenges in PD management:

Target Patient Population

Pharma Two B's therapies target patients in the mid-to-late stages of Parkinson's disease who require combination therapy to adequately control motor symptoms. The company estimates that approximately 60% of PD patients eventually require combination therapy, representing a substantial market opportunity.

Pipeline

P2B001: Pramipexole + Entacapone

P2B001 is Pharma Two B's lead product—a proprietary fixed-dose combination of pramipexole (a dopamine agonist) and entacapone (a COMT inhibitor). This combination addresses two key limitations in Parkinson's disease treatment: the need for dopamine agonist therapy and the benefits of COMT inhibition.

Mechanism of Action

P2B001 combines two well-established Parkinson's disease therapies with complementary mechanisms[@kalia2015]:

• Pramipexole: A non-ergot dopamine agonist that directly stimulates dopamine D2 and D3 receptors in the striatum, compensating for endogenous dopamine deficiency in PD patients.
• Entacapone: A selective and reversible COMT inhibitor that prevents the peripheral breakdown of levodopa, extending its plasma half-life and increasing CNS availability.

Clinical Development

P2B001 has undergone extensive clinical development:

• Phase I: Bioequivalence study demonstrating comparable pharmacokinetics to co-administration of individual products
• Phase II: Dose-finding study in PD patients confirming optimal dose ratio
• Phase III: Pivotal efficacy and safety study in advanced PD patients

Competitive Advantages

P2B001 offers several potential advantages over existing treatment options:

• Single-pill convenience: Eliminates the need for patients to take separate pramipexole and entacapone tablets
• Simplified regimen: Reduces medication management complexity
• Potential for improved adherence: Fewer pills may lead to better compliance
• Patent-protected formulation: Provides potential market exclusivity

P2B008: Next-Generation Combination

Pharma Two B's second product candidate, P2B008, is a novel fixed-dose combination therapy targeting unmet needs in Parkinson's disease management. While specific details are proprietary, the program represents the company's continued commitment to developing innovative combination approaches for PD.

Development Status

• Discovery: Completed
• Preclinical: Ongoing
• IND submission: Projected 2026

Preclinical Programs

Pharma Two B maintains additional discovery programs targeting:

• Novel dopamine agonist formulations
• Advanced COMT inhibitor combinations
• Disease-modifying approaches

Scientific Foundation

Parkinson's Disease Treatment Landscape

Parkinson's disease is the second most common neurodegenerative disorder, affecting approximately 10 million people worldwide. The disease is characterized by progressive loss of dopaminergic neurons in the substantia nigra, leading to the classic motor symptoms including tremor, bradykinesia, rigidity, and postural instability[@kalia2015].

Current treatment strategies for Parkinson's disease include:

Despite these options, many patients experience suboptimal symptom control, motor fluctuations, and dyskinesias, highlighting the need for improved therapeutic approaches[@lees2017].

Rationale for Combination Therapy

The rationale for fixed-dose combinations in Parkinson's disease is well-established[@pahwa2019]:

Pharma Two B's approach leverages these principles by combining two proven agents in a single, optimized formulation.

Clinical Development Strategy

Phase III Trial Design

P2B001's Phase III clinical trial was a randomized, double-blind, placebo-controlled study enrolled 400 patients with advanced Parkinson's disease experiencing motor fluctuations.

Key inclusion criteria:

• Diagnosis of Parkinson's disease (UK Brain Bank criteria)
• Hoehn and Yahr stage 2-4
• Stable levodopa regimen
• Documented motor fluctuations

• Primary: Change from baseline in UPDRS Parts II + III at week 15
• Secondary: Time to "on" state, "off" time reduction, Patient Global Impression of Change

Regulatory Strategy

Pharma Two B pursued regulatory approval through:

• FDA: NDA submission under 505(b)(2) pathway (relying on pramipexole and entacapone data)
• EMA: MAA submission through centralized procedure
• PMDA: Regulatory consultation in Japan

Competitive Landscape

Pharma Two B operates in a competitive Parkinson's disease treatment market:

| Company | Product | Mechanism | Status |
|---------|---------|-----------|--------|
| AbbVie | Duodopa/Duopa | Levodopa/carbidopa intestinal gel | Approved |
| Novartis | Stalevo | Levodopa/carbidopa/entacapone | Approved |
| Neurocrine | Ingrezza | VMAT2 inhibitor | Approved |
| Pharma Two B | P2B001 | Pramipexole + entacapone | Phase 3 |

P2B001 would compete primarily with Stalevo (levodopa/carbidopa/entacapone) and Duodopa, offering a differentiated mechanism through the inclusion of a dopamine agonist rather than levodopa.

Research Partnerships

Pharma Two B has established collaborations with:

• Tel Aviv University: Basic research and biomarker development
• Rabin Medical Center: Clinical trial operations in Israel
• European PD consortia: Clinical development partnerships
• Contract manufacturing organizations: GMP production

Funding History

| Round | Year | Amount | Lead Investors |
|-------|------|--------|----------------|
| Series A | 2008 | $5M | Israeli biotech investors |
| Series B | 2012 | $15M | Vertex Partners, Israel Healthcare Ventures |
| Series C | 2018 | $30M | Orbimed, Vivo Ventures |
| IPO | 2021 | $45M | NASDAQ listing |

Future Directions

Pharma Two B's long-term strategy includes:

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Dopamine Agonists](/mechanisms/dopamine-agonists)
• [COMT Inhibitors](/mechanisms/comt-inhibitors)
• [Levodopa Therapy](/therapeutics/levodopa-therapy)
• [Movement Disorders](/diseases/movement-disorders)

References